Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

Company Overview - Theravance Biopharma reported a narrower adjusted net loss of 6 cents per share for Q3 2024, compared to the Zacks Consensus Estimate of a loss of 10 cents, and a loss of 1 cent per share in the same quarter last year [2][3] - The total revenues for the quarter were $16.9 million, exceeding the Zacks Consensus Estimate of$16 million, and representing an 8% year-over-year increase driven by collaboration revenues from Viatris [3] Financial Details - The reported loss of 26 cents per share includes share-based compensation, non-cash impairment of long-lived assets, income tax expense, and non-cash interest expense, compared to a loss of 17 cents in the year-ago quarter [3] - Research and development expenses (excluding share-based compensation) were $8.2 million, up nearly 30$13 million [4] Cash Position and Guidance - As of September 30, 2024, Theravance had cash, cash equivalents, and marketable securities totaling $91.4 million, down from$96.1 million as of June 30, 2024 [5] - The company expects adjusted R&D expenses in the range of $30-$36 million and adjusted SG&A expenses between $45 million and$55 million for 2024 [6] Market Performance and Estimates - There has been an upward trend in estimates for Theravance over the past month, with a consensus estimate shift of -43.43% [8][9] - The stock currently holds a Zacks Rank 3 (Hold), indicating an expectation of an in-line return in the coming months [12] Industry Comparison - Theravance operates within the Zacks Medical - Drugs industry, where Ionis Pharmaceuticals reported revenues of $134 million for the last quarter, reflecting a year-over-year decline of 6.9$1.03 per share for the current quarter, indicating a significant change from the previous year, and holds a Zacks Rank 2 (Buy) [14]